Heparin monitoring during cardiac surgery. Part 1: validation of whole-blood heparin concentration and activated clotting time

Abstract

There is limited published data on the agreement between techniques for monitoring heparin levels. The aim of this study was to validate the Hepcon/HMS, with particular focus on the agreement with laboratory anti-Xa assay. The performances of two ACT instruments - Hemochron and HemoTec - were also evaluated, including an assessment for interchangeability. Blood samples from 42 adult cardiopulmonary bypass (CPB) patients were analysed for activated clotting time (ACT), whole-blood heparin concentration (Hepcon/HMS) and anti-factor Xa (anti-Xa) plasma heparin concentration. Agreement between measures was determined using the method of Bland and Altman. Simple analysis of agreement between the Hepcon and anti-Xa heparin revealed the Hepcon has a mean bias of -0.46 U/mL, with the limits of agreement ±1.12 U/mL. The comparison between ACT instruments indicated a mean difference of -96 seconds for the HemoTec, with limits of ±265 seconds. The Hepcon/HMS instrument displayed satisfactory agreement with anti-Xa plasma heparin concentration, as the expected variation would not be expected to cause problems in the clinical setting. Agreement between the two measurements of ACT may be satisfactory, provided each is assigned a different target value.

Get full access to this article

View all access options for this article.

References

Boisclair MD , Lane DA , Philippou H , Sheikh S , Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment-F(1+2) . Thromb Haemost 1993; 70: 253-258 .

Slaughter TF , LeBleu TH , Douglas JM , Leslie JB , Parker JK , Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers . Anesthesiology 1994; 80: 520-526 .

Gorman RC , Ziats NP , Rao AK et al. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass . J Thorac Cardiovasc Surg 1996; 111: 1-11 .

Davies GC , Sobel M , Salzman EW. Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass . Circulation 1980; 61: 808-814 .

Ray MJ , Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin . Thromb Haemost 1997; 78: 1021-1026 .

Hashimoto K , Yamagishi M , Sasaki T , Nakano M , Kurosawa H. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with sub-clinical plasma coagulation . Ann Thorac Surg 1994; 58: 799-804 .

Gravlee GP , Haddon WS , Rothberger HK et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of sub-clinical plasma coagulation . J Thorac Cardiovasc Surg 1990; 99: 518-527 .

Despotis GJ , Joist JH , Hogue CW et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather then ACT . Thromb Haemost 1996; 76: 902-908 .

Culliford AT , Gitel SN , Starr N et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass . Ann Surg 1981; 193: 105-111 .

10.

Esposito RA , Culliford AT , Colvin SB , Thomas SJ , Lackner H , Spencer FC. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass . J Thorac Cardiovasc Surg 1983; 85: 174-185 .

11.

Despotis GJ , Summerfield AL , Joist JH et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations . J Thorac Cardiovasc Surg 1994; 108: 1076-1082 .

12.

Martindale SJ , Shayevitz JR , D’Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery . J Cardiothorac Vasc Anesth 1996; 10: 458-463 .

13.

Bull BS , Korpman RA , Huse WM , Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols . J Thorac Cardiovasc Surg 1975; 69: 674-684 .

14.

Gruenwald C , de Souza V , Chan AK , Andrew M. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass . Perfusion 2000; 15: 203-209 .

15.

Despotis GJ , Joist JH , Joiner-Maier D et al. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements . Ann Thorac Surg 1995; 59: 106-111 .

16.

Despotis GJ , Joist JH , Goodnough LT , Santoro SA , Spitznagel E. Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements . J Thorac Cardiovasc Surg 1997; 113: 611-613 .

17.

Hashimoto K , Sasaki T , Hachiya T et al. Real time measurement of heparin concentration during cardio-pulmonary bypass . J Cardiovasc Surg 1999; 40: 645-651 .

18.

Wahr JA , Yun JH , Yang VC , Lee LM , Meyerhoff ME. A new method of measuring heparin levels in whole blood by protamine titration using a heparin-responsive electrochemical sensor . J Cardiothorac Vasc Anesth 1996; 10: 447-450 .

19.

Hardy JF , Bélisle S , Robitaille D , Perrault J , Roy M , Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X . J Thorac Cardiovasc Surg 1996; 112: 154-161 .

20.

Bland JM , Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement . Lancet 1986; 1: 307-310 .

21.

Hollis S. Analysis of method comparison studies . Ann Clin Biochem 1996; 33: 1-4 .

22.

de Swart CA , Nijmeyer B , Roelofs JM , Sixma JJ. Kinetics of intravenously administered heparin in normal humans . Blood 1982; 60: 1251-1258 .

23.

The Hepcon heparin assay - measurement of heparin anticoagulation by protamine titration . HemoTec Update 1989; 4.

24.

Kitchen S , Theaker J , Preston FE. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay . Blood Coagul Fibrinolysis 2000; 11: 137-144 .

25.

Kovacs MJ , Keeney M , MacKinnon K , Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin . Clin Lab Haematol 1999; 21: 55-60 .

26.

Young JA , Kisker CT , Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer . Ann Thorac Surg 1978; 26: 231-240 .

27.

Despotis GJ , Joist JH , Goodnough LT. Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes . Clin Chem 1997; 43: 1684-1696 .

28.

Raymond PD , Marsh NA. Alterations to haemostasis following cardiopulmonary bypass and the relationship of these changes to neurocognitive morbidity . Blood Coagul Fibrinolysis 2001; 12: 601-618 .

29.

Shirota K , Watanabe T , Takagi Y , Ohara Y , Usui A , Yasuura K. Maintenance of blood heparin concentration rather than activated clotting time better preserves the coagulation system in hypothermic cardiopulmonary bypass . Artif Organs 2000; 24: 49-56 .

30.

Avendaño A , Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty . J Am Coll Cardiol 1994; 23: 907-910 .